Perdagangan AstraZeneca PLC - GBP - AZNl CFD
Tambah ke favorit- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
Spread | 0.24 | ||||||||
Biaya inap posisi Long
Long position overnight fee
Kunjungi platform | -0.021808% | ||||||||
Biaya inap posisi short
Short position overnight fee
Kunjungi platform | -0.00011% | ||||||||
Waktu biaya inap | 21:00 (UTC) | ||||||||
Kuantitas min. yang diperdagangkan | 1 | ||||||||
Mata uang | GBP | ||||||||
Margin | 20% | ||||||||
Bursa efek | United Kingdom of Great Britain and Northern Ireland | ||||||||
Komisi perdagangan | 0% |
*Information provided by Capital.com
AstraZeneca PLC ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
Prev. Close* | 107.77 |
Open* | 107.73 |
1-Year Change* | 12.94% |
Day's Range* | 106.43 - 107.89 |
52 wk Range | 93.99-128.29 |
Average Volume (10 days) | 2.32M |
Average Volume (3 months) | 41.08M |
Market Cap | 166.66B |
P/E Ratio | 62.12 |
Shares Outstanding | 1.55B |
Revenue | 36.43B |
EPS | 1.73 |
Dividend (Yield %) | 2.21195 |
Beta | 0.28 |
Next Earnings Date | Apr 27, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Mar 17, 2023 | 107.67 | 0.06 | 0.06% | 107.61 | 109.11 | 107.29 |
Mar 16, 2023 | 107.87 | 2.10 | 1.99% | 105.77 | 108.15 | 105.77 |
Mar 15, 2023 | 106.29 | -0.60 | -0.56% | 106.89 | 107.85 | 106.19 |
Mar 14, 2023 | 106.47 | 0.22 | 0.21% | 106.25 | 107.17 | 105.51 |
Mar 13, 2023 | 106.69 | -0.18 | -0.17% | 106.87 | 108.47 | 105.43 |
Mar 10, 2023 | 106.63 | -0.74 | -0.69% | 107.37 | 108.49 | 105.77 |
Mar 9, 2023 | 108.53 | 0.78 | 0.72% | 107.75 | 109.33 | 107.69 |
Mar 8, 2023 | 107.95 | -0.36 | -0.33% | 108.31 | 108.89 | 107.75 |
Mar 7, 2023 | 108.29 | 2.40 | 2.27% | 105.89 | 108.93 | 105.89 |
Mar 6, 2023 | 107.33 | -0.06 | -0.06% | 107.39 | 108.05 | 106.99 |
Mar 3, 2023 | 107.93 | 0.06 | 0.06% | 107.87 | 108.73 | 107.71 |
Mar 2, 2023 | 108.35 | 1.22 | 1.14% | 107.13 | 108.45 | 107.13 |
Mar 1, 2023 | 107.85 | 1.20 | 1.13% | 106.65 | 108.83 | 106.65 |
Feb 28, 2023 | 108.53 | -1.45 | -1.32% | 109.98 | 110.98 | 108.13 |
Feb 27, 2023 | 110.70 | 1.20 | 1.10% | 109.50 | 111.50 | 109.50 |
Feb 24, 2023 | 110.84 | -0.24 | -0.22% | 111.08 | 112.28 | 110.82 |
Feb 23, 2023 | 112.32 | -2.48 | -2.16% | 114.80 | 114.80 | 111.56 |
Feb 22, 2023 | 114.74 | 0.02 | 0.02% | 114.72 | 115.88 | 114.26 |
Feb 21, 2023 | 115.52 | 0.50 | 0.43% | 115.02 | 116.66 | 115.02 |
Feb 20, 2023 | 115.08 | 0.30 | 0.26% | 114.78 | 115.52 | 114.42 |
AstraZeneca PLC - GBP Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total revenue | 23002 | 22465 | 22090 | 24384 | 26617 | 37417 |
Revenue | 23002 | 22465 | 22090 | 24384 | 26617 | 37417 |
Cost of Revenue, Total | 4044 | 4180 | 4246 | 4824 | 5270 | 9542 |
Gross Profit | 18958 | 18285 | 17844 | 19560 | 21347 | 27875 |
Total Operating Expense | 18100 | 18788 | 18703 | 21460 | 21455 | 36361 |
Selling/General/Admin. Expenses, Total | 8052 | 7650 | 8479 | 8964 | 9338 | 11519 |
Research & Development | 5664 | 5412 | 5266 | 5320 | 6094 | 8519 |
Depreciation / Amortization | 1529 | 1637 | 1945 | 1812 | 1897 | 3044 |
Unusual Expense (Income) | -802 | 320 | -953 | 863 | -763 | 3846 |
Other Operating Expenses, Total | -387 | -250 | -280 | -323 | -381 | -109 |
Operating Income | 4902 | 3677 | 3387 | 2924 | 5162 | 1056 |
Interest Income (Expense), Net Non-Operating | -616 | -764 | -775 | -766 | -716 | -819 |
Other, Net | -734 | -686 | -619 | -610 | -530 | -502 |
Net Income Before Taxes | 3552 | 2227 | 1993 | 1548 | 3916 | -265 |
Net Income After Taxes | 3406 | 2252 | 2050 | 1227 | 3144 | 115 |
Minority Interest | 93 | 133 | 105 | 108 | 52 | -3 |
Net Income Before Extra. Items | 3499 | 2385 | 2155 | 1335 | 3196 | 112 |
Net Income | 3499 | 3001 | 2155 | 1335 | 3196 | 112 |
Income Available to Common Excl. Extra. Items | 3499 | 2385 | 2155 | 1335 | 3196 | 112 |
Income Available to Common Incl. Extra. Items | 3499 | 3001 | 2155 | 1335 | 3196 | 112 |
Dilution Adjustment | 0 | 0 | 0 | |||
Diluted Net Income | 3499 | 3001 | 2155 | 1335 | 3196 | 112 |
Diluted Weighted Average Shares | 1266 | 1267 | 1267 | 1301 | 1313 | 1427 |
Diluted EPS Excluding Extraordinary Items | 2.76382 | 1.8824 | 1.70087 | 1.02613 | 2.43412 | 0.07849 |
Dividends per Share - Common Stock Primary Issue | 2.70034 | 2.73619 | 2.74532 | 2.89446 | 2.83031 | 2.84245 |
Diluted Normalized EPS | 2.5237 | 1.36938 | 0.85399 | 1.48501 | 1.88804 | 2.22705 |
Interest Expense (Income) - Net Operating | -161 | 0 | 0 | |||
Total Extraordinary Items | 616 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2021 | Q1 2022 | |
---|---|---|---|---|---|
Total revenue | 7320 | 8220 | 9866 | 12011 | 11390 |
Revenue | 7320 | 8220 | 9866 | 12011 | 11390 |
Cost of Revenue, Total | 1920 | 2193 | 3824 | 3069 | 2279 |
Gross Profit | 5400 | 6027 | 6042 | 8942 | 9111 |
Total Operating Expense | 5425 | 7093 | 11540 | 12303 | 10512 |
Selling/General/Admin. Expenses, Total | 2498 | 2574 | 2986 | 4082 | 3057 |
Research & Development | 1638 | 1801 | 2153 | 2927 | 2186 |
Depreciation / Amortization | 384 | 385 | 1209 | 1066 | 1098 |
Unusual Expense (Income) | -920 | 269 | 1405 | 1007 | 2025 |
Other Operating Expenses, Total | -95 | -129 | -37 | 152 | -133 |
Operating Income | 1895 | 1127 | -1674 | -292 | 878 |
Interest Income (Expense), Net Non-Operating | -287 | -363 | -327 | -344 | -325 |
Net Income Before Taxes | 1608 | 764 | -2001 | -636 | 553 |
Net Income After Taxes | 1562 | 550 | -1651 | -346 | 388 |
Minority Interest | -1 | 0 | -1 | -1 | -2 |
Net Income Before Extra. Items | 1561 | 550 | -1652 | -347 | 386 |
Net Income | 1561 | 550 | -1652 | -347 | 386 |
Income Available to Common Excl. Extra. Items | 1561 | 550 | -1652 | -347 | 386 |
Income Available to Common Incl. Extra. Items | 1561 | 550 | -1652 | -347 | 386 |
Dilution Adjustment | 0 | ||||
Diluted Net Income | 1561 | 550 | -1652 | -347 | 386 |
Diluted Weighted Average Shares | 1319 | 1318 | 1496 | 1550 | 1561 |
Diluted EPS Excluding Extraordinary Items | 1.18347 | 0.4173 | -1.10428 | -0.22387 | 0.24728 |
Dividends per Share - Common Stock Primary Issue | 0 | 0.89599 | 0 | 1.96577 | 0 |
Diluted Normalized EPS | 0.49507 | 0.5736 | 0.13971 | 1.00645 | 1.33953 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total Current Assets | 13262 | 13150 | 15591 | 15563 | 19544 | 26244 |
Cash and Short Term Investments | 5902 | 4554 | 5680 | 6218 | 7992 | 6398 |
Cash | 782 | 784 | 893 | 755 | 1182 | 1461 |
Cash & Equivalents | 4236 | 2540 | 3938 | 4614 | 6650 | 4868 |
Short Term Investments | 884 | 1230 | 849 | 849 | 160 | 69 |
Total Receivables, Net | 4001 | 4275 | 4345 | 5181 | 5651 | 8795 |
Accounts Receivable - Trade, Net | 2583 | 2802 | 2995 | 3813 | 3956 | 6324 |
Total Inventory | 2334 | 3035 | 2890 | 3193 | 4024 | 8983 |
Prepaid Expenses | 998 | 1258 | 1436 | 865 | 1735 | 1512 |
Other Current Assets, Total | 27 | 28 | 1240 | 106 | 142 | 556 |
Total Assets | 62526 | 63354 | 60651 | 61377 | 66729 | 105363 |
Property/Plant/Equipment, Total - Net | 6848 | 7615 | 7421 | 8335 | 8917 | 10171 |
Property/Plant/Equipment, Total - Gross | 13451 | 14639 | 14639 | 15852 | 17110 | 18495 |
Accumulated Depreciation, Total | -6603 | -7024 | -7218 | -7517 | -8193 | -8324 |
Goodwill, Net | 11658 | 11825 | 11707 | 11668 | 11845 | 19997 |
Intangibles, Net | 27586 | 26188 | 21959 | 20833 | 20947 | 42387 |
Long Term Investments | 826 | 1036 | 922 | 1459 | 1147 | 1237 |
Note Receivable - Long Term | 901 | 847 | 515 | 348 | 325 | 504 |
Other Long Term Assets, Total | 1445 | 2693 | 2536 | 3171 | 4004 | 4823 |
Total Current Liabilities | 15256 | 16383 | 16292 | 18117 | 20307 | 22594 |
Accounts Payable | 2990 | 3611 | 1720 | 1774 | 2350 | 2824 |
Accrued Expenses | 3095 | 3794 | 5148 | 5085 | 4994 | 8079 |
Notes Payable/Short Term Debt | 94 | 152 | 160 | 154 | 370 | 294 |
Current Port. of LT Debt/Capital Leases | 2213 | 2095 | 1594 | 1856 | 2016 | 1599 |
Other Current Liabilities, Total | 6864 | 6731 | 7670 | 9248 | 10577 | 9798 |
Total Liabilities | 47672 | 48394 | 48183 | 48250 | 51107 | 66095 |
Total Long Term Debt | 14501 | 15560 | 17359 | 16217 | 17994 | 28888 |
Long Term Debt | 14495 | 15560 | 17359 | 15730 | 17505 | 28134 |
Capital Lease Obligations | 6 | 0 | 0 | 487 | 489 | 754 |
Deferred Income Tax | 3956 | 3995 | 3286 | 2490 | 2918 | 6206 |
Minority Interest | 1815 | 1682 | 1576 | 1469 | 16 | 19 |
Other Liabilities, Total | 12144 | 10774 | 9670 | 9957 | 9872 | 8388 |
Total Equity | 14854 | 14960 | 12468 | 13127 | 15622 | 39268 |
Common Stock | 316 | 317 | 317 | 328 | 328 | 387 |
Additional Paid-In Capital | 4351 | 4393 | 4427 | 7941 | 7971 | 35126 |
Retained Earnings (Accumulated Deficit) | 10187 | 10250 | 7724 | 4858 | 7323 | 3755 |
Total Liabilities & Shareholders’ Equity | 62526 | 63354 | 60651 | 61377 | 66729 | 105363 |
Total Common Shares Outstanding | 1265.23 | 1266.22 | 1267.04 | 1312.14 | 1312.67 | 1549.4 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Total Current Assets | 18735 | 27274 | 26691 | 26244 | 22647 |
Cash and Short Term Investments | 7765 | 15629 | 7149 | 6398 | 5823 |
Cash & Equivalents | 7636 | 15567 | 7067 | 6329 | 5762 |
Short Term Investments | 129 | 62 | 82 | 69 | 61 |
Total Receivables, Net | 6628 | 6842 | 8854 | 10307 | 9050 |
Accounts Receivable - Trade, Net | 6281 | 6356 | 8258 | 9644 | 8683 |
Total Inventory | 4278 | 4762 | 10528 | 8983 | 7624 |
Other Current Assets, Total | 64 | 41 | 160 | 556 | 150 |
Total Assets | 64926 | 73641 | 107221 | 105363 | 100273 |
Property/Plant/Equipment, Total - Net | 8849 | 9031 | 10162 | 10171 | 10015 |
Goodwill, Net | 11765 | 11798 | 20081 | 19997 | 19963 |
Intangibles, Net | 20347 | 20006 | 44104 | 42387 | 41265 |
Long Term Investments | 1060 | 1120 | 1585 | 1237 | 1237 |
Note Receivable - Long Term | 549 | 565 | 811 | 895 | 864 |
Other Long Term Assets, Total | 3621 | 3847 | 3787 | 4432 | 4282 |
Total Current Liabilities | 21513 | 22222 | 23649 | 22594 | 22740 |
Payable/Accrued | 17370 | 17729 | 18663 | 18938 | 17864 |
Notes Payable/Short Term Debt | 407 | 392 | 500 | 294 | 724 |
Current Port. of LT Debt/Capital Leases | 1851 | 2502 | 2473 | 1599 | 1570 |
Other Current Liabilities, Total | 1885 | 1599 | 2013 | 1763 | 2582 |
Total Liabilities | 50496 | 57965 | 67477 | 66095 | 63933 |
Total Long Term Debt | 17874 | 24601 | 28939 | 28888 | 28805 |
Long Term Debt | 17410 | 24109 | 28206 | 28134 | 28081 |
Capital Lease Obligations | 464 | 492 | 733 | 754 | 724 |
Deferred Income Tax | 2823 | 2927 | 6400 | 6206 | 5626 |
Minority Interest | 16 | 17 | 168 | 19 | 19 |
Other Liabilities, Total | 8270 | 8198 | 8321 | 8388 | 6743 |
Total Equity | 14430 | 15676 | 39744 | 39268 | 36340 |
Common Stock | 328 | 328 | 387 | 387 | 387 |
Additional Paid-In Capital | 7976 | 7980 | 35118 | 35126 | 35131 |
Retained Earnings (Accumulated Deficit) | 6126 | 7368 | 4239 | 3755 | 822 |
Total Liabilities & Shareholders’ Equity | 64926 | 73641 | 107221 | 105363 | 100273 |
Total Common Shares Outstanding | 1312.74 | 1312.79 | 1549.14 | 1549.4 | 1549.45 |
- Annual
- Quarterly
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Net income/Starting Line | 3552 | 2227 | 1993 | 1548 | 3916 | -265 |
Cash From Operating Activities | 4145 | 3578 | 2618 | 2969 | 4799 | 5963 |
Cash From Operating Activities | 2357 | 3036 | 3753 | 3762 | 3149 | 6530 |
Non-Cash Items | -1601 | -483 | -1276 | -103 | -332 | 141 |
Cash Taxes Paid | 412 | 454 | 537 | 1118 | 1562 | 1743 |
Cash Interest Paid | 677 | 698 | 676 | 774 | 733 | 721 |
Changes in Working Capital | -163 | -1202 | -1852 | -2238 | -1934 | -443 |
Cash From Investing Activities | -3969 | -2328 | 963 | -657 | -285 | -11058 |
Capital Expenditures | -2314 | -1620 | -1371 | -2460 | -2606 | -2200 |
Other Investing Cash Flow Items, Total | -1655 | -708 | 2334 | 1803 | 2321 | -8858 |
Cash From Financing Activities | -1324 | -2936 | -2044 | -1765 | -2203 | 3649 |
Financing Cash Flow Items | 18 | -20 | -67 | 4 | -101 | -178 |
Total Cash Dividends Paid | -3561 | -3519 | -3484 | -3592 | -3572 | -3856 |
Issuance (Retirement) of Stock, Net | 47 | 43 | 34 | 3525 | 30 | 29 |
Issuance (Retirement) of Debt, Net | 2172 | 560 | 1473 | -1702 | 1440 | 7654 |
Foreign Exchange Effects | 21 | -66 | -38 | 5 | 12 | -62 |
Net Change in Cash | -1127 | -1752 | 1499 | 552 | 2323 | -1508 |
Mar 2021 | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 1608 | 2372 | 371 | -265 | 553 |
Cash From Operating Activities | 1934 | 2826 | 4545 | 5963 | 3232 |
Cash From Operating Activities | 797 | 1550 | 4338 | 6530 | 1309 |
Non-Cash Items | -1162 | -761 | -507 | 141 | -12 |
Cash Taxes Paid | 332 | 869 | 1198 | 1743 | 228 |
Cash Interest Paid | 187 | 323 | 522 | 721 | 194 |
Changes in Working Capital | 691 | -335 | 343 | -443 | 1382 |
Cash From Investing Activities | 555 | 319 | -10145 | -11058 | -168 |
Capital Expenditures | -469 | -822 | -1482 | -2200 | -363 |
Other Investing Cash Flow Items, Total | 1024 | 1141 | -8663 | -8858 | 195 |
Cash From Financing Activities | -2731 | 4558 | 4700 | 3649 | -3740 |
Financing Cash Flow Items | -23 | -22 | -28 | -178 | -997 |
Total Cash Dividends Paid | -2469 | -2469 | -3856 | -3856 | -2971 |
Issuance (Retirement) of Stock, Net | 5 | 9 | 10 | 29 | 5 |
Issuance (Retirement) of Debt, Net | -244 | 7040 | 8574 | 7654 | 223 |
Foreign Exchange Effects | -67 | -52 | -73 | -62 | -9 |
Net Change in Cash | -309 | 7651 | -973 | -1508 | -685 |
Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
---|---|---|---|---|---|---|
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5099 | 100893184 | 1200 | 2023-01-31 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 4.2 | 65092368 | 768 | 2023-01-31 | LOW |
Capital Research Global Investors | Investment Advisor | 4.12 | 63852512 | 752 | 2023-01-31 | LOW |
Investor AB | Private Equity | 3.33 | 51608948 | 608 | 2023-01-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 2.8464 | 44114976 | -1215991 | 2022-12-14 | LOW |
Capital World Investors | Investment Advisor | 1.7648 | 27351981 | 2675871 | 2022-12-14 | LOW |
BlackRock Advisors (UK) Limited | Investment Advisor/Hedge Fund | 1.1934 | 18495433 | 289630 | 2023-03-01 | LOW |
BlackRock Investment Management (UK) Ltd. | Investment Advisor/Hedge Fund | 1.1402 | 17670785 | 0 | 2023-03-01 | LOW |
GQG Partners, LLC | Investment Advisor | 1.0697 | 16579162 | 1036509 | 2022-12-14 | MED |
State Street Global Advisors (UK) Ltd. | Investment Advisor/Hedge Fund | 0.6303 | 9768142 | 18173 | 2023-03-01 | LOW |
Nuveen LLC | Pension Fund | 0.6158 | 9543355 | 495683 | 2022-12-14 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.5411 | 8386244 | -95567 | 2022-12-14 | LOW |
Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.5082 | 7875720 | 214842 | 2022-12-14 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 0.5022 | 7783223 | -7029 | 2023-03-01 | LOW |
Aviva Investors Global Services Limited | Investment Advisor/Hedge Fund | 0.5003 | 7754095 | 612331 | 2023-03-01 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 0.4726 | 7325050 | 98350 | 2023-03-01 | LOW |
Handelsbanken Kapitalförvaltning AB | Investment Advisor/Hedge Fund | 0.47 | 7284582 | 919455 | 2023-02-28 | LOW |
Union Investment Privatfonds GmbH | Investment Advisor | 0.3731 | 5782579 | -203480 | 2022-12-31 | LOW |
Royal London Asset Management Ltd. | Investment Advisor/Hedge Fund | 0.3705 | 5741791 | 5792 | 2023-03-01 | MED |
Schroder Investment Management Ltd. (SIM) | Investment Advisor/Hedge Fund | 0.3701 | 5735207 | 34985 | 2023-03-01 | LOW |
Mengapa memilih Capital.com? Biarlah angka kami yang berbicara.
Capital.com Group 500000+
Trader
92000+
Klien aktif per bulan
$53000000+
Volume investasi per bulan
$30000000+
Coba sekarang Penarikan tiap bulan
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Industry: | Pharmaceuticals (NEC) |
1 Francis Crick Avenue
CAMBRIDGE
CAMBRIDGESHIRE CB2 0AA
GB
Income Statement
- Annual
- Quarterly
People also watch
Masih mencari broker yang bisa Anda percayai?
Bergabung dengan 500.000+ trader di seluruh dunia yang telah memilih trading bersama Capital.com